Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $204K | $1.14M | $4.04M |
| Revenue growth | — | 458.3% | 254.7% |
| Operating income | -$55.4M | -$115M | -$191M |
| Operating margin | -27180.9% | -10067.3% | -4722.1% |
| Net income | -$48.6M | -$88.0M | -$161M |
| Net margin | -23827.0% | -7729.5% | -3985.0% |
| EPS (diluted) | -$15.65 | -$1.41 | -$2.08 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$45.7M | -$78.7M | -$132M |
| Capital expenditures | — | $234K | $134K |
| Free cash flow | — | -$78.9M | -$132M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $8.27M | $257M | $32.5M |
| Total assets | $199M | $755M | $792M |
| Total liabilities | $14.5M | $21.4M | $39.0M |
| Long-term debt | — | $0.00 | $3.00M |
| Shareholders' equity | -$123M | $733M | $753M |
| Retained earnings | -$130M | -$218M | -$379M |
| Shares (wtd avg diluted) | 4.33M | 62.5M | 77.3M |
Every figure is extracted from CG Oncology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.